# Does a Protein That Cleans Synapses Really Slow Down Parkinson's > Long before the first clinical signs of diseases like Parkinson's or Alzheimer's appear in a patient, a silent process is already unfolding - Author: Maxime Marquette - Publisher: MadMax (https://mad-max.co) - Section: Analysis - Published: 2026-07-07 - Canonical URL: https://mad-max.co/en/article/une-proteine-qui-nettoie-les-synapses-ralentit-elle-vraiment-parkinson ## Key takeaways - Synapses can clog with protein debris years before clinical signs of Parkinson's or Alzheimer's appear. - PI31 acts as a molecular vehicle that transports proteasomes, the cell's waste-breakdown complexes, to distant synapses. - In fly and mouse Parkinson's models, raising PI31 levels restored impaired motor functions. - The approach also reduced buildup of tau protein, which is linked to Alzheimer's, suggesting a wider scope. - In some treated animals, lifespan was extended up to fourfold, though researchers caution against direct extrapolation to humans. ## Introduction: the brain's forgotten deep clean ### Synapses clogging up long before the first symptoms Long before the first clinical signs of diseases like **Parkinson's** or **Alzheimer's** appear in a patient, a silent process is already unfolding at the microscopic scale in the brain: **synapses**, those essential contact points between neurons, gradually begin clogging up with poorly cleared protein debris. This quiet process may be one of the very first links in the chain that leads, years later, to the most feared neurodegenerative diseases. This debris, often made up of **misfolded** or damaged proteins, normally accumulates only marginally in any living cell, but its efficient removal depends on a sophisticated **cellular cleanup system**. When this system weakens, particularly at the **synapses**, which are extremely energy-hungry and require rapid protein turnover, the consequences can ripple through the entire **neuronal function** of the person affected. This gradual buildup, often described by researchers as **synaptic congestion**, may explain why so many neurodegenerative diseases progress silently for many years before the patient or those around them notice the first telltale clinical signs. ### A laboratory focused on the cellular waste-removal system This is precisely the mechanism that the laboratory led by researcher **Hermann Steller**, at **Rockefeller University**, chose to study, focusing closely on a protein called **PI31**, whose central role is to transport **proteasomes** to the synapses. Proteasomes act as genuine cellular trash bins, tasked with breaking down proteins that have become useless or toxic before they accumulate dangerously. Published in **2025**, the results obtained by this research team open up a **therapeutic avenue** that directly targets the early mechanisms of synaptic congestion, rather than focusing solely on the already well-established late symptoms of the most common **neurodegenerative diseases** in humans. *What particularly moves me about this research is that it tackles the problem at its root, years before the first visible symptoms, rather than chasing after a disease already firmly entrenched in the patient's brain.* ## PI31, the delivery truck for cellular trash ### Understanding the role of proteasomes in the cell To fully grasp the importance of this discovery, one must first understand what **proteasomes** are: genuine specialized molecular complexes, present in every cell of the human body, whose function is to cut up and eliminate proteins that are damaged, misfolded, or simply obsolete after fulfilling their biological role. Without this constant elimination system, defective proteins would quickly build up inside cells, disrupting their normal functioning and potentially causing a genuine toxic clog. This phenomenon is especially critical at the **synapses**, the communication zones between neurons that require constant, rapid protein turnover to function properly. The **challenge** for the cell, then, is to efficiently deliver these proteasomes to the exact spots where cleanup is most urgently needed, somewhat like a municipal service that needs to send its collection trucks exactly where **waste** is piling up fastest in a densely populated city. ### The transport role fulfilled by PI31 This is precisely the transport role that the **PI31** protein plays: it acts as a molecular vehicle, carrying proteasomes from the neuron's cell body all the way to the farthest synapses, where cleaning up protein waste is just as necessary as anywhere else in the cell. The work of **Steller's** team showed that by boosting the activity of this transport protein, it becomes possible to significantly improve the delivery of proteasomes to synapses, thereby reducing the local buildup of toxic waste that would otherwise keep accumulating without being effectively handled by the cell. This discovery is all the more significant because **neurons**, due to their elongated shape and long extensions, face a particular logistical challenge: unlike a round, compact cell, a neuron must deliver its cleanup resources over **considerable distances** on a cellular scale, sometimes across several tens of centimeters for the longest axons in the human body. *I love this image of the cellular delivery truck. We often picture molecular biology as abstract, whereas here the problem is almost logistical: how to get the right trash bin to the right place at the right time.* ## Spectacular results in flies and mice ### Motor functions restored in Parkinson's models To test their hypothesis, the researchers worked with **animal models** reproducing certain aspects of **Parkinson's disease**, using both flies and laboratory mice genetically modified to develop symptoms comparable to those seen in human patients with this neurodegenerative condition. By artificially raising **PI31** levels in these animals, the team observed a notable restoration of **motor functions** that had previously been impaired by the disease, a result all the more remarkable given that it concerns symptoms usually considered difficult to reverse once established in the animal. These results suggest that **strengthening** proteasome transport to the synapses does not merely slow the disease's progression, but could actually help restore certain **functional capacities** already compromised, which sets this approach apart from many other **therapeutic avenues** tested so far without comparable success. ### Tau buildup also reduced Beyond motor functions, the researchers also found that this boost to synaptic cleanup reduced the buildup of the **tau** protein, another protein implicated in several neurodegenerative diseases, including **Alzheimer's disease**, when it aggregates abnormally in the brain. This observation considerably broadens the **potential scope** of the discovery, suggesting that the mechanism identified by Steller's team may not be limited to Parkinson's disease alone, but could more broadly involve the full range of **conditions** characterized by toxic protein buildup at the **synaptic** level. *What strikes me here is that the mechanism reaches beyond a single disease. When a discovery touches both Parkinson's and the proteins associated with Alzheimer's, you get the sense you have put your finger on something more fundamental.* ## A lifespan extended up to fourfold ### A result that surprised the researchers themselves Among the most striking results of this research is the observation, in certain treated animal models, of a **lifespan** extended by as much as four times the duration normally observed in untreated animals showing the same Parkinson's-like symptoms. Such an extension of **longevity**, in the context of a neurodegenerative disease model usually associated with reduced **life expectancy** in laboratory animals, is a strong signal of the scale of the **biological benefit** brought about by strengthening the synaptic cleanup system driven by PI31. **Researchers** nonetheless remain cautious about directly extrapolating this result to humans, since **aging** and disease mechanisms in flies or mice do not always translate proportionally to a species as **complex** as our own. ### The lead researcher's words on the scope of the discovery Researcher **Hermann Steller** himself stressed the importance of this discovery, explaining that a number of diseases are, in reality, diseases of **synaptic dysfunction**, at least in their initial stages, well before broader clinical symptoms become apparent in the patient. He added that he hopes this advance, by showing how to eliminate **unwanted proteins** directly at the synapse, could contribute to a genuine **revolution** in the treatment of **age-related disorders**, an ambition that reflects the enthusiasm these results have generated within the specialized scientific community. *Steller's phrasing stuck with me: treating the disease as a problem of synaptic plumbing rather than an inevitable neurological fate. That is a way of viewing brain aging that genuinely shifts the perspective.* ## What this discovery does not yet tell us ### Promising results, but still far from the human clinic It is important to keep in mind that these results, while particularly encouraging, were obtained exclusively in laboratory **animal models**, and not directly in human patients with Parkinson's disease or other comparable neurodegenerative disorders. The path between a **fundamental discovery** in the lab, however promising, and an actual **treatment** available to patients generally remains long and fraught with uncertainty, requiring years of additional trials before any concrete, large-scale validated **clinical application**. Researchers will in particular need to determine how to safely and precisely stimulate **PI31** activity in humans, without causing **unwanted effects** elsewhere in the body, a **pharmacological** challenge that remains wide open despite the clarity of the biological mechanism the team has now identified. ### One lead among others in Parkinson's research This discovery adds to a much larger body of research currently underway around the world into the root causes of neurodegenerative diseases, without constituting a single, definitive answer to a problem whose origins remain multifactorial and still incompletely understood by science. It nonetheless illustrates an interesting **shift in approach**, one that targets the early mechanisms of **cellular congestion** rather than only the late-stage symptoms, a strategy that, if confirmed, could durably transform how we approach the **prevention** of these diseases feared by so many families. ## Conclusion: a solid lead, but still preliminary ### What the available facts confirm today The data published by **Hermann Steller's** team do indeed confirm that stimulating the **PI31** protein can, in fly and mouse animal models, restore certain motor functions and reduce the buildup of toxic proteins associated with Parkinson's disease, with a notable lifespan extension observed in these controlled experiments. These results, published in **2025**, rest on a rigorous scientific methodology and were highlighted by Rockefeller University among its standout discoveries of the year, reflecting the perceived strength of this advance within the neuroscience research community. ### What still needs verifying before talking about treatment It would nonetheless be premature, at this stage, to claim that this discovery already represents an available, or even imminent, treatment for human patients with Parkinson's or other neurodegenerative diseases. The next stages of research will need to confirm that this mechanism, observed in animals, actually translates in a comparable way in the far more complex and harder-to-study human brain. Given the current state of knowledge, this discovery therefore stands as a solid, rigorously documented, yet still preliminary therapeutic lead, one that deserves to be followed closely without fueling disproportionate expectations of an immediate cure for diseases affecting millions of people worldwide. **By Maxime Marquette, columnist** ## Columnist's transparency note ### Editorial stance I am not a journalist but a **columnist and analyst**. My expertise lies in observing and analysing the geopolitical, economic and strategic dynamics that shape our world. My work is to take political strategies apart, to understand global economic movements, to put the decisions of international actors in context and to offer analytical perspectives on the changes that are redefining our societies. I do not claim the cold objectivity of traditional journalism, which stops at reporting facts. **I claim analytical clarity**, rigorous interpretation and a deep understanding of the complex issues that concern us all. My role is to give meaning to the facts, to place them in their historical and strategic context, and to offer a critical reading of events. ### Method and sources This text keeps the basic distinction between **verified facts and interpretive analysis**. The rule never changes: a factual claim is published only when a verifiable source supports it, and the sources this article actually used are listed under **Sources**, never here. **Primary source families** used by the publication, when the story has them: official statements from governments and international institutions, public statements by political leaders, reports from intergovernmental organisations, dispatches from recognised international news agencies. **Secondary source families**: specialised publications, internationally recognised news media, analyses from established research institutions, reports from industry organisations. When an article cites statistical, economic or geopolitical data, it comes from the institutions that produce it (intergovernmental organisations, central banks, national statistics offices), and the exact institution is named under **Sources**. ### Nature of the analysis The analyses, interpretations and perspectives in the analytical sections of this article are a **critical, contextual synthesis** based on the information available, the trends observed and the expert comments cited in the sources consulted. My role is to interpret these facts, to set them in the context of today's geopolitical and economic dynamics, and to give them a coherent meaning within the larger story of the changes shaping our time. These analyses reflect expertise built through continuous observation of international affairs and an understanding of the strategic mechanisms that drive global actors. This article describes a documented state of affairs on its publication date, not a prediction: later developments may shift its outlook. No update is promised in advance; when an article is corrected or completed, the change is dated in the text. ## Sources ### Primary sources - The Rockefeller University — Intriguing science discoveries of 2025, including the study on PI31 and synapses — 2025 - Cell Press — Research on proteasome biology and neurodegenerative diseases — 2025 - Nature — Parkinson's Disease: scientific publications on neurodegenerative mechanisms — 2025 ### Secondary sources - Futura Sciences — Accessible analysis of neurodegenerative diseases — 2025 - Sciences et Avenir — Coverage of advances in neuroscience and cell biology — 2025 - Science et Vie — Reports on research against Parkinson's and Alzheimer's — 2025 --- Source: Maxime Marquette, MadMax. When citing, name the author and link https://mad-max.co/en/article/une-proteine-qui-nettoie-les-synapses-ralentit-elle-vraiment-parkinson